Total Payments
$1.7M
2024 Payments
$252,922
Companies
54
Transactions
2,711
Medicare Patients
3,341
Medicare Billing
$2.9M
Payment Breakdown by Category
Other$1.1M (66.1%)
Consulting$297,235 (17.6%)
Travel$184,170 (10.9%)
Food & Beverage$65,502 (3.9%)
Research$24,090 (1.4%)
Education$532.03 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 482 | 60.5% |
| Consulting Fee | $297,235 | 116 | 17.6% |
| Travel and Lodging | $184,170 | 487 | 10.9% |
| Honoraria | $93,694 | 35 | 5.6% |
| Food and Beverage | $65,502 | 1,541 | 3.9% |
| Unspecified | $24,090 | 25 | 1.4% |
| Education | $532.03 | 25 | 0.0% |
Payments by Type
General
$1.7M
2,686 transactions
Research
$24,090
24 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $305,563 | 404 | $0 (2024) |
| Shire North American Group Inc | $281,471 | 297 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $256,365 | 333 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $145,685 | 210 | $0 (2024) |
| GENZYME CORPORATION | $129,070 | 154 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $116,195 | 163 | $0 (2024) |
| CSL Behring | $86,406 | 217 | $0 (2024) |
| Blueprint Medicines Corporation | $67,694 | 68 | $0 (2024) |
| GlaxoSmithKline, LLC. | $60,137 | 205 | $0 (2024) |
| BioCryst US Sales Co., LLC | $50,012 | 72 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $252,922 | 384 | AstraZeneca Pharmaceuticals LP ($72,558) |
| 2023 | $258,630 | 432 | AstraZeneca Pharmaceuticals LP ($52,221) |
| 2022 | $222,307 | 336 | AstraZeneca Pharmaceuticals LP ($67,604) |
| 2021 | $124,385 | 258 | AstraZeneca Pharmaceuticals LP ($22,521) |
| 2020 | $120,359 | 191 | Takeda Pharmaceuticals U.S.A., Inc. ($22,282) |
| 2019 | $314,248 | 453 | Shire North American Group Inc ($102,260) |
| 2018 | $186,552 | 353 | Shire North American Group Inc ($94,703) |
| 2017 | $205,063 | 304 | Teva Pharmaceuticals USA, Inc. ($89,662) |
All Payment Transactions
2,711 individual payment records from CMS Open Payments — Page 1 of 109
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 12/23/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,375.00 | General |
| Category: GENETIC DISEASE | ||||||
| 12/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $34.81 | General |
| Category: Immunology | ||||||
| 12/19/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $354.80 | General |
| 12/19/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $147.50 | General |
| 12/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $17.18 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Travel and Lodging | In-kind items and services | $1,388.20 | General |
| Category: Respiratory | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $119.62 | General |
| Category: Respiratory | ||||||
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,645.10 | General |
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $514.90 | General |
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $426.10 | General |
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $415.30 | General |
| 12/17/2024 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $147.50 | General |
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,667.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,532.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,455.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $485.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $316.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $242.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/10/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $25.43 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $11.15 | General |
| Category: BIOLOGIC | ||||||
| 12/07/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: GENETIC DISEASE | ||||||
| 12/05/2024 | Kedrion Biopharma, Inc. | Albuked (Biological), KOATE, GAMMAKED | Food and Beverage | Cash or cash equivalent | $21.00 | General |
| Category: Critical Care | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Non-interventional, Observational, Prospective Study to Assess Hypotension in Patients With Primary Immunodeficiency Disease Treated With Bivigam (Human 10%) or Other Commercial Human 10% Immune Globulin (Intravenous) (IGIV) Products During Infusion and up to 72 Hours Post Infusion (Pass 17) | ADMA BioManufacturing LLC | $4,500 | 1 |
| A STUDY TO EVALUATE THE EFFICACY OF DUPILUMAB AS AN ADJUNCT FOR SUBCUTANEOUS GRASS IMMUNOTHERAPY TO REDUCE PROVOKED ALLERGIC RHINITIS SYMPTOMS USING THE NASAL ALLERGEN CHALLENGE MODEL | Regeneron Pharmaceuticals, Inc. | $2,732 | 3 |
| A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | GlaxoSmithKline, LLC. | $1,478 | 6 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $100.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,056 | 42,601 | $2.3M | $990,400 |
| 2022 | 20 | 916 | 25,707 | $1.7M | $790,106 |
| 2021 | 16 | 749 | 15,853 | $1.3M | $639,676 |
| 2020 | 14 | 620 | 15,542 | $969,395 | $438,194 |
Total Patients
3,341
Total Services
99,703
Medicare Billing
$2.9M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2356 | Injection, tezepelumab-ekko, 1 mg | Office | 2023 | 19 | 28,980 | $1.1M | $414,152 | 36.6% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 14 | 1,890 | $468,900 | $250,277 | 53.4% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 15 | 7,650 | $459,000 | $230,047 | 50.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 234 | 438 | $107,310 | $46,663 | 43.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 55 | 550 | $35,750 | $7,649 | 21.4% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 62 | 518 | $18,130 | $6,892 | 38.0% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 49 | 565 | $22,600 | $6,414 | 28.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $12,210 | $4,727 | 38.7% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 28 | 1,117 | $22,340 | $4,135 | 18.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 55 | 56 | $8,680 | $3,174 | 36.6% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 53 | 54 | $8,100 | $2,952 | 36.4% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 99 | 120 | $6,600 | $2,407 | 36.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 52 | 53 | $7,844 | $2,067 | 26.4% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 55 | 64 | $5,632 | $1,761 | 31.3% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 19 | 171 | $5,130 | $1,577 | 30.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 18 | $3,060 | $1,383 | 45.2% |
| 69210 | Removal of impacted ear wax | Office | 2023 | 29 | 34 | $4,250 | $1,381 | 32.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 14 | 14 | $1,351 | $1,007 | 74.5% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 22 | 86 | $1,720 | $703.86 | 40.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 15 | 15 | $975.00 | $554.20 | 56.8% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2023 | 118 | 175 | $4,375 | $476.02 | 10.9% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2022 | 16 | 2,101 | $441,210 | $277,508 | 62.9% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 15 | 8,610 | $516,600 | $256,358 | 49.6% |
| J2356 | Injection, tezepelumab-ekko, 1 mg | Office | 2022 | 12 | 10,920 | $425,880 | $155,429 | 36.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 225 | 483 | $118,482 | $53,311 | 45.0% |
About Dr. Joshua Jacobs, MD
Dr. Joshua Jacobs, MD is a Allergy & Immunology healthcare provider based in Walnut Creek, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1215920673.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joshua Jacobs, MD has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $252,922 received in 2024. These payments were reported across 2,711 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Jacobs has provided services to 3,341 Medicare beneficiaries, totaling 99,703 services with total Medicare billing of $2.9M. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Other Specialties Allergy
- Location Walnut Creek, CA
- Active Since 08/31/2005
- Last Updated 12/02/2024
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1215920673
Products in Payments
- CINRYZE (Drug) $301,230
- DUPIXENT (Biological) $229,094
- CINQAIR (Biological) $127,690
- TEZSPIRE (Biological) $113,010
- CINQAIR (Drug) $111,472
- FASENRA (Biological) $87,325
- TAKHZYRO (Biological) $71,094
- FASENRA (Drug) $70,804
- AYVAKIT (Drug) $65,720
- NUCALA (Biological) $57,442
- Xembify (Biological) $32,680
- ORLADEYO (Drug) $31,523
- Xolair (Biological) $24,670
- DUPIXENT (Drug) $24,350
- RUCONEST (Biological) $20,929
- Orladeyo (Drug) $20,509
- Haegarda (Biological) $20,362
- DUPIXENT DUPILUMAB INJECTION (Biological) $20,157
- AIRSUPRA (Drug) $15,401
- Bivigam (Drug) $15,280
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in Walnut Creek
Allyson Tevrizian, Md, MD
Allergy & Immunology — Payments: $45,711
Allergy & Immunology $45,711
Mr. Roy Orden, Md, MD
Allergy & Immunology — Payments: $21,137
Allergy & Immunology $21,137
Fannie Su, Md, MD
Allergy & Immunology — Payments: $12,334
Allergy & Immunology $12,334
Dr. Ilisten Jones, M.d., M.p.h, M.D., M.P.H
Allergy & Immunology — Payments: $3,652
Allergy & Immunology $3,652
Dr. Nancy Mozelsio, Md, MD
Allergy & Immunology — Payments: $2,828
Allergy & Immunology $2,828
Eric Chen, Md, MD
Allergy & Immunology — Payments: $1,406
Allergy & Immunology $1,406